Normocalcemic primary hyperparathyroidism — «new era» in diagnosis of an old disease

During the last century, primary hyperparathyroidism (PHPT) passed from the category of rare severe diseases to a common endocrine disorder with a prevalence of mild forms. Over the last 10—20 years, widespread screening for osteoporosis has led to the «new era» in diagnosis of PHPT when patients are diagnosed at the stage of an isolated elevated parathyroid hormone with stable normal serum calcium levels and the absence of secondary causes of hyperparathyroidism. This phenomenon was called normocalcemic primary hyperparathyroidism (nPHPT); according to the literature data, its prevalence varies from 0.4 to 16.7% due to the lack of unified diagnostic criteria. The clinical picture and natural history of the disease are poorly explored, and it is still unclear if nPHPT is a separate disease entity or if it is an early stage of hypercalcemic PHPT. A number of studies have shown that complications of nPHPT (osteoporosis and urolithiasis) are similar to those of the symptomatic form of PHPT despite stable normocalcemia. However, these patients were often referred to specialized metabolic centers due to a decrease in the bone mass or nephrolithiasis, therefore the rate of complications in them may be overestimated. There are also controversial data on an increased risk of cardiovascular diseases due to metabolic disorders in this pathology.

As a new clinical nosology, normocalcemic PHPT was first officially recognized at the Third International Workshop on Management of Asymptomatic PHPT in 2008, but there have been yet no common recommendations for its treatment. Some studies have shown a response to medical therapy and improved indicators of bone mineral density after parathyroidectomy in these patients. According to the experts of the Fourth International Workshop in 2014, nPHPT remains one of the key topics for further research.

: primary hyperparathyroidism, normocalcemic primary hyperparathyroidism, serum, calcium, vitamin D, osteoporosis

1. Дедов И.И., Мокрышева Н.Г., Мирная С.С., и др. Эпидемиология первичного гиперпаратиреоза в России (первые зезультаты по базе данных ФГУ ЭНЦ) // Проблемы Эндокринологии. – 2011. – Т.57. – №3 – С. 3—10. [Dedov II, Mokrysheva NGg, Mirnaia SS, et al. Epidemiology of primary hyperparathyroidism in Russia (the first results from the database of Federal State Institution «Endocrinological Research Centre»). Problems Of Endocrinology. 2011;57(3):3-10. (In Russ)]. doi: 10.14341/probl20115733-10

2. Bilezikian JP, Potts JTJr, Fuleihan Gel H, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st Century. J Clin Endocrinol Metab. 2002;87(12):5353-5361. doi: 10.1210/jc.2002-021370

3. Дедов И.И., Мельниченко Г.А., Мокрышева Н.Г., и др. Первичный гиперпаратиреоз: клиника, диагностика, дифференциальная диагностика, методы лечения // Проблемы Эндокринологии. — 2011. — Т. 62. — №6. — С. 40—77. [Dedov II, Melnichenko GA, Mokrysheva NG, et al. Primary hyperparathyroidism: the clinical picture, diagnostics, differential diagnostics, and methods of treatment. Problems of Endocrinology. 2017;62(6):40-77. (In Russ.)]. doi:10.14341/probl201662640-77

4. Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism. Arquivos Brasileiros De Endocrinologia & Metabologia. 2010;54(2):106-109. doi: 10.1590/s0004-27302010000200004

5. Mather HG. Hyperparathyroidism with normal serum calcium. BMJ. 1953;2(4833):424-425. doi: 10.1136/bmj.2.4833.424

6. Kontogeorgos G, Trimpou P, Laine Cm, et al. Normocalcaemic, vitamin D-sufficient hyperparathyroidism — high prevalence and low morbidity in tht general population: a long-term follow-up study. The WHO Monica Project. Gothenburg, Sweden. Clin Endocrinol (Oxf). 2015;83(2):277-284. doi: 10.1111/cen.12819

7. Rejnmark L, Vestergaard P, Brot C, Mosekilde L. Increased fracture risk in normocalcemic postmenopausal women with high parathyroid hormone levels: a 16-year follow-up study. Calcif Tissue Int. 2010;88(3):238-245. doi: 10.1007/s00223-010-9454-0

8. Eastell R, Brandi ML, Costa AG, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocr Metab. 2014;99(10):3570-3579. doi: 10.1210/jc.2014-1414

9. Pawlowska M, Cusano NE. An overview of normocalcemic primary hyperparathyroidism. Curr Opin Endocrinol Diabetes Obes. 2015;22(6):413-421. doi: 10.1097/med.0000000000000198

10. Rejnmark L, Vestergaard P, Heickendorff L, et al. Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. J Intern Med. 2001;250(2):144-153. doi: 10.1046/j.1365-2796.2001.00868.x

11. Mallette LE, Khouri K, Zengotita H, et al. Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume. J Clin Endocr Metab. 1989;68(3):654-660. doi: 10.1210/jcem-68-3-654

12. Chesnut CH, Mcclung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. The American Journal of Medicine. 1995;99(2):144-152. doi: 10.1016/s0002-9343(99)80134-x

13. Mcclung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821-831. doi: 10.1056/nejmoa044459

14. Makras P, Polyzos SA, Papatheodorou A, et al. Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clin Endocrinol (Oxf). 2013;79(4):499-503. doi: 10.1111/cen.12188

15. Coe FL, Canterbury JM, Firpo JJ, Reiss E. Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J Clin Invest. 1973;52(1):134-142. doi: 10.1172/jci107156

16. Worcester EM, Coe FL. New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol. 2008;28(2):120-132. doi: 10.1016/j.semnephrol.2008.01.005

17. Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom. 2013;16(1):33-39. doi: 10.1016/j.jocd.2012.12.001

18. Berger C, langsetmo L, hanley D, et al. Relative prevalence of normocalcemic and hypercalcemic hyperparathyroidism in a community-dwelling cohort. Program of the 33rd annual meeting of the american society of bone and mineral research. San Diego CA, 2011:abstract 0173.

19. Lundgren E, Rastad J, Thurfjell E, et al. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery. 1997;121(3):287-294. doi: 10.1016/s0039-6060(97)90357-3

20. Vignali E, Cetani F, Chiavistelli S, et al. Normocalcemic primary hyperparathyroidism: a survey in a small village of southern italy. Endocrine Connections. 2015;4(3):172-178. doi: 10.1530/ec-15-0030

21. Cusano NE, Maalouf NM, Wang PY, et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocr Metab. 2013;98(7):2734-2741. doi: 10.1210/jc.2013-1300

22. Majid H, Khan AH, Riaz M, et al. Identifying parathyroid hormone disorders and their phenotypes through a bone health screening panel: it’s not simple vitamin D deficiency! Endocr Pract. 2016;22(7):814-821. doi: 10.4158/ep161206.or

23. Marques TF, Vasconcelos R, Diniz E, et al. Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat? Arquivos Brasileiros De Endocrinologia & Metabologia. 2011;55(5):314-317. doi: 10.1590/s0004-27302011000500003

24. Мокрышева Н.Г. Первичный гиперпаратиреоз. Эпидемиология, клиника, современные принципы диагностики и лечения: Дис. … д-ра мед. наук. М. 2011. [Mokrysheva NG. Pervichnyi giperparatireoz. Epidemiologiya, klinika, sovremennye printsipy diagnostiki i lecheniya [Dissertation]. M. 2011. (In Russ.)].

25. Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab. 1988;67(6):1294-1298. doi: 10.1210/jcem-67-6-1294

26. Lowe H, Mcmahon DJ, Rubin MR, et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92(8):3001-3005. doi: 10.1210/jc.2006-2802

27. Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab. 2003;88(10):4641-4648. doi: 10.1210/jc.2002-021404

28. Cosman F. Estrogen protection against bone resorbing effects of parathyroid hormone infusion: assessment by use of biochemical markers. Ann Intern Med. 1993;118(5):337. doi: 10.7326/0003-4819-118-5-199303010-00003

29. Wade TJ, Yen TWF, Amin AL, Wang TS. Surgical management of normocalcemic primary hyperparathyroidism. World J Surg. 2012;36(4):761-766. doi: 10.1007/s00268-012-1438-y

30. Siperstein AE. Normocalcemic hyperparathyroidism. Arch Surg. 1992;127(10):1157.doi: 10.1001/archsurg.1992.01420100015003

31. Tordjman KM, Greenman Y, Osher E, et al. Characterization of normocalcemic primary hyperparathyroidism. The American Journal of Medicine. 2004;117(11):861-863. doi: 10.1016/j.amjmed.2004.06.037

32. Amaral LM, Queiroz DC, Marques TF, et al. Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos. 2012;2012:128352. doi: 10.1155/2012/128352

33. Spivacow FR, Sahag Durán A, Zanchetta MB. Hiperparatiroidismo primario normocalcémico. Medicina (B Aires). 2014;74(6):457-461.

34. Garcia-Martin A, Reyes-Garcia R, Munoz-Torres M. Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine. 2012;42(3):764-766. doi: 10.1007/s12020-012-9694-z

35. Hedback Oden. Increased risk of death from primary hyperparathyroidism — an update. Eur J Clin Invest. 1998;28(4):271-276. doi: 10.1046/j.1365-2362.1998.00289.x

36. Вороненко И.В., Сыркин А.Л., Рожинская Л.Я., Мельниченко Г.А. Гиперпаратиреоз и патология сердечно-сосудистой системы // Остеопороз и остеопатиии. — 2006. — Т. 2. — №2. — С. 33—41. [Voronenko IV, Syrkin AL, Rozhinskaya LYa, Mel’nichenko GA. Giperparatireoz i patologiya serdechno-sosudistoi systemy. Osteoporosis and Osteopathy. 2006;2(2):33-41. (In Russ.)].

37. Lind L, Ljunghall S. Hypertension, primary hyperparathyroidism and the parathyroid hypertensive factor. Blood Press. 2009;2(1):4-5. doi: 10.3109/08037059309077520

38. Ljunghall S, Lithell H, Vessby B, Wide L. Glucose and lipoprotein metabolism in primary hyperparathyroidism. Effects of parathyroidectomy. Eur J Endocrinol. 1978;89(3):580-589. doi: 10.1530/acta.0.0890580

39. Khaleeli AA, Johnson JN, Taylor WH. Prevalence of glucose intolerance in primary hyperparathyroidism and the benefit of parathyroidectomy. Diabetes Metab Res Rev. 2007;23(1):43-48. doi: 10.1002/dmrr.637

40. Cakir I, Unluhizarci K, Tanriverdi F, et al. Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism. Endocrine. 2012;42(2):419-422. doi: 10.1007/s12020-012-9627-x

41. Tordjman KM, Yaron M, Izkhakov E, et al. Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism. Eur J Endocrinol. 2010;162(5):925-933. doi: 10.1530/eje-09-1067

42. Yener Ozturk F, Erol S, Canat Mm, et al. Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients. Endocr J. 2016;63(2):111-118. doi: 10.1507/endocrj.ej15-0392

43. Hagstrom E. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol. 2006;155(1):33-39. doi: 10.1530/eje.1.02173

44. Temizkan S, Kocak O, Aydin K, et al. Normocalcemic hyperparathyroidism and insulin resistance. Endocr Pract. 2015;21(1):23-29. doi: 10.4158/ep14195.or

45. Rubin MR, Silverberg SJ. Glucose intolerance and primary hyperparathyroidism: an unresolved relationship. Endocrine. 2012;42(2):231-233. doi: 10.1007/s12020-012-9674-3

46. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocr Metab. 2014;99(10):3561-3569. doi: 10.1210/jc.2014-1413

47. Khan AA, Bilezikian JP, Kung AWC, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocr Metab. 2004;89(7):3319-3325. doi: 10.1210/jc.2003-030908

48. Cesareo R, Di Stasio E, Vescini F, et al. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos Int. 2014;26(4):1295-1302. doi: 10.1007/s00198-014-3000-2

49. Brardi S, Cevenini G, Verdacchi T, et al. Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study. Archivio Italiano Di Urologia E Andrologia. 2015;87(1):66. doi: 10.4081/aiua.2015.1.66

50. Koumakis E, Souberbielle J-C, Sarfati E, et al. Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocr Metab. 2013;98(8):3213-3220. doi: 10.1210/jc.2013-1518

51. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, et al. Serum intact parathyroid hormone in a random population sample of men and women: relationship to anthropometry, life-style factors, blood pressure, snd vitamin D. Calcif Tissue Int. 1995;56(2):104-108. doi: 10.1007/bf00296339

52. Touvier M, Deschasaux M, Montourcy M, et al. Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values. J Clin Endocr Metab. 2014;99(4):1196-1203. doi: 10.1210/jc.2013-3349

53. Invernizzi M, Carda S, Righini V, et al. Different PTH response to oral peptone load and oral calcium load in patients with normocalcemic primary hyperparathyroidism, primary hyperparathyroidism, and healthy subjects. Eur J Endocrinol. 2012;167(4):491-497. doi: 10.1530/Eje-12-0362